Hong Kong Stock Exchange

watch now
Hutchmed eyes drug licensing M&A opportunities following HK listing: CEO
watch now
VIDEO03:02
CNBC ProHutchmed eyes drug licensing M&A opportunities following HK listing: CEO
CNBC ProThis China tech stock could rise near 50% despite regulatory risks: Analyst
CNBC ProLong-term Asia-focused investors can't afford to be underweight this stock: CFRA